CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Bupivacaine 5 mg +1 moredrug
Likely dose
Bupivacaine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04205344
NCT04205344Phase 4Completed
CompareCT.gov

Effectiveness of Subarachnoid Hyperbaric Bupivacaine on Mean Arterial Blood Pressure in Pregnant Patients With Obesity Operated by Cesarean Section

Hospital Civil de Guadalajara·interventional·Posted Dec 19, 2019·Updated Dec 23, 2019

In Brief

A Phase 4 clinical trial evaluating Bupivacaine 5 mg and Bupivacaine 10 mg for Anesthesia, Obstetrical. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study evaluates the effect of subarachnoid hyperbaric bupivacaine on mean arterial blood pressure (MAP) of pregnant patients with obesity undergoing cesarean section half of the patients will receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg while the other half will receive a dose of 10 mg

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia, Obstetrical
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartFeb 1, 2017
Primary CompletionJun 30, 2017
Study CompletionMay 30, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.5 years ago

Interventions

Bupivacaine 5 mgdrug

Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg

Bupivacaine 10 mgdrug

Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg